Back to DE D. E. Shaw & Co., Inc.
CHRS
Showing 0 of 22 quarters
Position history for DED. E. Shaw & Co., Inc.'s holdings in Coherus Oncology, Inc.
No. D. E. Shaw exited its CHRS (Coherus Oncology) position in Q1 2024. Its Q4 2023 13F listed 127,610 shares worth $424,941. D. E. Shaw already held CHRS in its Q4 2018 13F, the earliest on record, and held it in 21 quarterly 13F filings.
Current Value
—
Current Shares
—
Total Value Change
$0
Total Shares Change
0
No position history available for this security.